Optiscan Imaging Limited announced an exclusive collaboration with Prolucid Technologies, to develop Artificial Intelligence (AI) algorithms and telepathology workflows using its confocal laser endomicroscopy (CLE) technology. The project, anticipated to take 18-24 months including a series of key developmental milestones, will take images from Optiscan's platform technology, and develop a processing pipeline that will display results of an AI
algorithm to clinicians for immediate decision-making during clinical workflows. The application will be used by trained healthcare professionals in a variety of hospital and clinical settings, with a focus on oral imaging and cancer detection in the first instance. The partnership with the Ontario-based software developer has been established to further enhance the clinical capability of Optiscan's technology, with the goal of developing a Software as a Medical Device (SaMD) application that will support image collection, processing, and tissue analytics to detect the presence of pre- cancerous and cancerous cells.